Mayne Pharma Group Limited (ASX: MYX) has secured licensed rights to a generic topical dermatology product from Encube Ethicals Pvt Ltd. Encube has an outstanding track record of innovative and generic topical drug development.
- New product is complementary to the company’s existing portfolio of branded and generic dermatology products.
Applications for the product approval are filed with US Food and Drug Administration, which is expected in calendar year 2020.
By 12:58 PM AEST, MYX was trading at $0.56, down by 0.88% relative to the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.